On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Pain has plagued us since the beginning of humankind, its origins explored in frustrated fits and starts by philosophers and doctors attempting to understand and mitigate it. From his Lyceum in ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

There is good news for those with acute pain, as the FDA has approved a first-of-its-kind pain medication, and it’s one ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Climate change may be struggling for airtime as voters suffer acute hip pocket pain, but that doesn't mean support for action ...

Several of these signaling pathways, such as phosphatidylinositol 3-kinase ... As described above, recent evidence has demonstrated that inhibition of EREG reverses or enhances hypersensitivity in ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

We and others have also reported that acute alcohol consumption produces analgesic effects ... and biological functions in these brain areas known to play a role in pain. Canonical pathway analysis ...

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr. Jianguo Cheng, from the Cleveland Clinic, constantly works with patients with ...